Can I read 23P In vivo multi-dimensional CRISPR screens identify LGALS2 as an immunotherapy target in triple-negative breast cancer on EtoBox?

23P In vivo multi-dimensional CRISPR screens identify LGALS2 as an immunotherapy target in triple-negative breast cancer by P. Ji; Y. Gong; M. Jin; X. Hu; G. Di; Z. Shao is a Medicine article available to read on EtoBox.

What is 23P In vivo multi-dimensional CRISPR screens identify LGALS2 as an immunotherapy target in triple-negative breast cancer about?

Results: A total of 3,858 breast cancers and integrated clinicopathologic data were collected in our biobank (2012)(2013)(2014)(2015)(2016)(2017)(2018)(2019)(2020)(2021)(2022). The samples, stored at -80 C, included tumor (n1⁄43,858), matched non-neoplastic tissues (n1⁄42,101; 55%), and biofluids (n1⁄43,423; 89%), i.e. blood, serum, and plasma. For 1,774 (45%) patients both the normal tissue and blood samples were stored. Subtypes included 3,188 (82.6%) invasive carcinoma of no special type, 428 (11.1%) lobular, 134 (3.5%) mixed ductal-lobular, and 84 (2.2%) special types. Grade, stage, and molecular subtypes were available for all patients. Biomarkers were carefully annotated (e.g. we were able to retrieve 1,478 HER2-low breast cancers samples). All patients signed the Scientific Research Participation Agreement.Conclusions: B4MED at IEO is an invaluable source of biomaterials that in the last decade led to remarkable scientific innovations related to new biomarkers and novel drugs, for increasingly personalized treatment strategies designed for breast cancer patients. The next challenge is to integrate digital and molecular pathology data to take advantage of machine learning pro

Who reads 23P In vivo multi-dimensional CRISPR screens identify LGALS2 as an immunotherapy target in triple-negative breast cancer?

Author

P. Ji; Y. Gong; M. Jin; X. Hu; G. Di; Z. Shao

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Medicine (Health Sciences)